Our previous International Union of Basic and Clinical Pharmacology report on the
nomenclature and classification of adenosine receptors (2011) contained a number of …

Adenosine plays a very significant role in modulating striatal glutamatergic and
dopaminergic neurotransmission. In the present essay we first review the extensive …

The adenosine A2A receptor subtype is recognized as a non-dopaminergic
pharmacological target for the treatment of neurodegenerative disorders, notably …

Mutations that constitutively activate G protein-coupled receptors (GPCRs), known as
constitutively activating mutations (CAMs), modify cell signaling and interfere with drugs …

Introduction Levodopa remains the gold-standard Parkinson's disease (PD) treatment, but
the inevitable development of motor complications has led to intense activity in pursuit of its …

Apathy is a disabling syndrome associated with poor functional outcomes that is common
across a broad range of neurological and psychiatric conditions. Currently, there are no …

KW-6356 is a novel adenosine A2A (A2A) receptor antagonist/inverse agonist, and its
efficacy as monotherapy in Parkinson's disease (PD) patients has been reported …

Adenosine is an immunosuppressive factor in the tumor microenvironment mainly through
activation of the A2A adenosine receptor (A2AR), which is a mechanism hijacked by tumors …

Abstract Adenosine A 2A-receptors (A 2A R) and dopamine D 2-receptors (D 2 R) are known
to work together in a synergistic manner. Inhibiting A 2A Rs by genetic or pharmacological …

The A2A adenosine receptor, a member of the P1 purinergic receptor family, plays a crucial
role in the pathophysiology of different neurodegenerative illnesses, including Alzheimer's …